JP7266030B2 - リンパ球悪性疾患を治療するための方法 - Google Patents

リンパ球悪性疾患を治療するための方法 Download PDF

Info

Publication number
JP7266030B2
JP7266030B2 JP2020522722A JP2020522722A JP7266030B2 JP 7266030 B2 JP7266030 B2 JP 7266030B2 JP 2020522722 A JP2020522722 A JP 2020522722A JP 2020522722 A JP2020522722 A JP 2020522722A JP 7266030 B2 JP7266030 B2 JP 7266030B2
Authority
JP
Japan
Prior art keywords
treatment
pharmaceutical composition
compound
patient
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020522722A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501140A (ja
JP2021501140A5 (enExample
Inventor
フー，ウェイ
Original Assignee
チョーチアン ディーティーアールエム バイオファーマ コーポレーション リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チョーチアン ディーティーアールエム バイオファーマ コーポレーション リミテッド filed Critical チョーチアン ディーティーアールエム バイオファーマ コーポレーション リミテッド
Publication of JP2021501140A publication Critical patent/JP2021501140A/ja
Publication of JP2021501140A5 publication Critical patent/JP2021501140A5/ja
Priority to JP2023067105A priority Critical patent/JP2023080357A/ja
Application granted granted Critical
Publication of JP7266030B2 publication Critical patent/JP7266030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020522722A 2017-10-27 2018-10-26 リンパ球悪性疾患を治療するための方法 Active JP7266030B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023067105A JP2023080357A (ja) 2017-10-27 2023-04-17 リンパ球悪性疾患を治療するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762578081P 2017-10-27 2017-10-27
US62/578,081 2017-10-27
PCT/US2018/057660 WO2019084369A1 (en) 2017-10-27 2018-10-26 METHODS OF TREATING LYMPHOID MALIGNANCIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023067105A Division JP2023080357A (ja) 2017-10-27 2023-04-17 リンパ球悪性疾患を治療するための方法

Publications (3)

Publication Number Publication Date
JP2021501140A JP2021501140A (ja) 2021-01-14
JP2021501140A5 JP2021501140A5 (enExample) 2021-11-25
JP7266030B2 true JP7266030B2 (ja) 2023-04-27

Family

ID=64557117

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020522722A Active JP7266030B2 (ja) 2017-10-27 2018-10-26 リンパ球悪性疾患を治療するための方法
JP2023067105A Ceased JP2023080357A (ja) 2017-10-27 2023-04-17 リンパ球悪性疾患を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023067105A Ceased JP2023080357A (ja) 2017-10-27 2023-04-17 リンパ球悪性疾患を治療するための方法

Country Status (10)

Country Link
US (1) US11622965B2 (enExample)
EP (1) EP3700532A1 (enExample)
JP (2) JP7266030B2 (enExample)
KR (1) KR20200128510A (enExample)
CN (1) CN112165945A (enExample)
AU (1) AU2018354356A1 (enExample)
CA (1) CA3096973A1 (enExample)
IL (1) IL274033A (enExample)
TW (1) TW201922256A (enExample)
WO (1) WO2019084369A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
US20230255975A1 (en) * 2020-06-25 2023-08-17 Celgene Corporation Methods for treating cancer with combination therapies
WO2022272060A1 (en) * 2021-06-24 2022-12-29 Reservoir Neuroscience, Inc. Ep2 antagonist compounds
EP4642450A2 (en) * 2022-12-28 2025-11-05 Reservoir Neuroscience, Inc. Ep2 antagonist compounds
KR20250131823A (ko) 2023-03-31 2025-09-03 아벨제타 인크. Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016065078A (ja) 2010-06-03 2016-04-28 ファーマサイクリックス，インク． ブルトン型チロシンキナーゼ（Ｂｔｋ）の阻害剤の使用
JP2016516817A (ja) 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのＴＯＲキナーゼ阻害剤及びＩＭｉＤ化合物を含む組合せ療法
WO2016145935A1 (zh) 2015-03-19 2016-09-22 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
JP2017518276A (ja) 2014-04-29 2017-07-06 チョーチアン ディーティーアールエム バイオファーマ コーポレーション リミテッド ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
EP1921149A1 (en) 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
SG10202107066WA (en) 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN102115476A (zh) 2011-03-23 2011-07-06 常州大学 一种2H-吡唑并[3,4-d]嘧啶衍生物及合成方法
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
WO2013191965A1 (en) 2012-06-18 2013-12-27 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
JP6261580B2 (ja) 2012-07-30 2018-01-17 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化イブルチニブ
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
WO2014143807A2 (en) 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
CU24400B1 (es) 2013-04-08 2019-04-04 Bayer Pharma AG Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
EP2983670A4 (en) 2013-04-08 2017-03-08 Pharmacyclics LLC Ibrutinib combination therapy
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2014187319A1 (en) 2013-05-21 2014-11-27 Jiangsu Medolution Ltd Substituted pyrazolopyrimidines as kinases inhibitors
US20170360796A1 (en) * 2014-12-23 2017-12-21 Pharmacyclics Llc Btk inhibitor combinations and dosing regimen
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
EP3328380A4 (en) 2015-07-31 2019-07-24 Pharmacyclics LLC INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016065078A (ja) 2010-06-03 2016-04-28 ファーマサイクリックス，インク． ブルトン型チロシンキナーゼ（Ｂｔｋ）の阻害剤の使用
JP2016516817A (ja) 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのＴＯＲキナーゼ阻害剤及びＩＭｉＤ化合物を含む組合せ療法
JP2017518276A (ja) 2014-04-29 2017-07-06 チョーチアン ディーティーアールエム バイオファーマ コーポレーション リミテッド ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物
WO2016145935A1 (zh) 2015-03-19 2016-09-22 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lancet Oncology，2016年，Vol.17，pp.48-56
Oncotarget，2014年，Vol.5, No.13，pp.4990-5001

Also Published As

Publication number Publication date
CN112165945A (zh) 2021-01-01
EP3700532A1 (en) 2020-09-02
KR20200128510A (ko) 2020-11-13
JP2021501140A (ja) 2021-01-14
IL274033A (en) 2020-06-30
WO2019084369A1 (en) 2019-05-02
US11622965B2 (en) 2023-04-11
US20200289517A1 (en) 2020-09-17
TW201922256A (zh) 2019-06-16
JP2023080357A (ja) 2023-06-08
AU2018354356A1 (en) 2020-05-14
CA3096973A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
JP7266030B2 (ja) リンパ球悪性疾患を治療するための方法
AU2020297596A1 (en) Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
AU2019273850B2 (en) Methods of treating myeloproliferative neoplasms
US10882863B2 (en) Compounds for reducing c-Myc in c-Myc overexpressing cancers background
WO2015142867A1 (en) Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells
KR20160135230A (ko) 암의 치료를 위한 병용 요법으로서의 에리불린 및 mTOR 억제제의 용도
US12533357B2 (en) Treatment for acute myeloid leukemia or myelodysplastic syndrome
JP7389486B2 (ja) 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤
JP7571024B2 (ja) 抗ｃｃｒ４抗体抵抗性のがんの治療剤
TWI849001B (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
AU2023372369B2 (en) Combination therapy for treating cancer
CA3240885A1 (en) Pharmaceutical combination comprising abemaciclib and a pi3k and/or a mtor inhibitor for the treatment of mantle cell lymphoma
US20250387383A1 (en) Methods of treating myeloproliferative neoplasms
KR20210115375A (ko) Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물
WO2025166537A1 (en) Methods of treatment using an ezh2 modulator
WO2025217597A1 (en) A cdk9 inhibitor for use in the treatment of cancer in a subject having an asxl1 mutation
EA049145B1 (ru) Способы лечения миелопролиферативных неоплазий
NZ795224A (en) Preservation of immune response during chemotherapy regimens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211011

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230320

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230417

R150 Certificate of patent or registration of utility model

Ref document number: 7266030

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250